Share, Send, or Save


Alexion is advancing its rare disease pipeline with highly innovative product candidates in multiple therapeutic areas, including severe and life-threatening complement disorders and metabolic diseases.

Full Pipeline

Advanced Clinical Development
Early Clinical
Filter by:
Generate PDF

Soliris® (eculizumab) for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase: Market


Soliris® (eculizumab) for Atypical Hemolytic Uremic Syndrome (aHUS)
Phase: Market


Eculizumab for Refractory Generalized Myasthenia Gravis (gMG)
Phase: Registration


Eculizumab for Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase: Advanced Clinical Development


Eculizumab for Antibody Mediated Rejection (AMR)
Phase: Advanced Clinical Development


ALXN1210 for PNH
Phase: Advanced Clinical Development


ALXN1210 for aHUS
Phase: Advanced Clinical Development


Phase: Early Clinical Development


Strensiq® (asfotase alfa) for Hypophosphatasia (HPP)
Phase: Market


Kanuma® (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D)
Phase: Market


Multiple Complement
Phase: Preclinical